AI Tracks Protein Deficiencies in Weight Loss Drug Users

Real-world study finds GLP-1 RA users struggle to meet protein needs, highlighting need for personalized nutrition guidance.

Apr. 10, 2026 at 8:04am

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the intricate molecular structure of a protein, conceptually representing the nutritional deficiencies uncovered in users of weight loss drugs.Advanced imaging techniques uncover the hidden nutritional challenges faced by users of powerful weight loss medications.Milan Today

A new study using an AI-powered nutrition tracking app found that adults with overweight or obesity taking the weight loss drugs semaglutide and tirzepatide tend to eat significantly less, putting them at risk of protein deficiencies. The research, presented at the European Congress on Obesity, suggests these powerful medications may transform obesity care, but also underscore the urgent need for proactive nutritional monitoring and personalized dietary guidance to support long-term health.

Why it matters

While GLP-1 receptor agonist (GLP-1 RA) medications like semaglutide and tirzepatide produce impressive weight loss, concerns remain about whether this comes at the cost of meaningful muscle loss. Protecting muscle mass should be a central goal, as it depends on sufficient protein intake and regular physical activity. This study highlights how reduced appetite from GLP-1 RAs can make it harder for users to meet their protein needs, making nutrition guidance critical.

The details

Researchers analyzed 5,741 days of data from 332 adults with overweight or obesity using a mobile dietary tracking app. They compared intake between 116 GLP-1 RA users and 216 non-users. The analysis found GLP-1 RA users reported significantly lower total energy, protein, carbohydrate and fat intake compared to non-users. However, weight-adjusted protein intake was critically low in GLP-1 RA users, with 88% falling below national recommendations, versus 69% in non-users. GLP-1 RA users were also much more likely to skip meals, reducing opportunities for adequate protein distribution.

  • The study analyzed data collected between July 2025 and February 2026.

The players

Dr. Valentina Vinelli

Lead author of the study and part of the metabolic health research team at IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University in Milan, Italy.

Dr. Rebecca De Lorenzo

Leader of the metabolic health research team at IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University in Milan, Italy.

Professor Patrizia Rovere Querini

Leader of the metabolic health research team at IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University in Milan, Italy.

Robin Health

Collaborated with the research team on the AI-powered nutrition tracking app used in the study.

Got photos? Submit your photos here. ›

What they’re saying

“While GLP-1 RAs produce impressive weight loss, the question of whether meaningful muscle loss accompanies fat loss with these therapies is still hotly debated. What remains universally agreed, however, is that protecting muscle mass should be a central goal of any weight-loss programme.”

— Dr. Valentina Vinelli, Lead author

“While GLP-1 RAs medications are transforming obesity care, we still know very little about how they affect eating patterns and nutrient intake. What's more, many people taking GLP-1 RAs receive little or no systematic guidance on diet quality, protein intake, or micronutrient adequacy.”

— Dr. Valentina Vinelli, Lead author

What’s next

In future work, the researchers plan to explore how GLP-1 RAs affect the intake of other key nutrients beyond protein and examine how real-time mobile apps could help people maintain healthy eating and lifestyle habits throughout their weight loss journey.

The takeaway

This study highlights the critical need for proactive nutritional monitoring and personalized dietary guidance to be integrated alongside obesity treatments like GLP-1 RAs. Protecting muscle mass and overall health should be a priority, not just weight loss.